Yes. I was just curious how far they are along. There seem to be so many biotech companies with great ideas that are all at preclinical stage. It seems it’s a huge bottleneck. I think the funding issue isn’t just confined to biotech there’s been a major contraction in other industries as well. But things seem to be beginning to move again slowly. I recently listened to an interview with the CEO of Oneskin and they would like to do human trials on a pill but it’s too expensive.
1 Like
do you have a sense from the conference, from informal conversations, that how many of those attendees are on rapamycin and other longevity combinations?
It does raise some interesting thoughts. Though being given a body that has been grown in a vat for twenty five years doesn’t sound all that appealing.
2 Likes
Funny… I had not thought about how long it might take to grow full organs / a body. You bring up a good point, even if was for organs… I wonder how long it would take to grow. More than a few years doesn’t seem to be viable (from a business perspective). But obviously, lots of science needs to be worked out whatever the case.
I can’t see anyone waiting 15 or 20 years for a new “body”, but I guess companies like scotch and whisky companies do bottle products and put them away for 15 or 20 years until they have “aged” properly and are ready to sell, so perhaps this model could also work in biology (its just never been done as of yet).
1 Like
Funny you bring this up. I sent a text to a friend today saying how well the conference went, and commenting how “Where else in the world could I sit down at a table for lunch with 9 other random people and 80% of them are taking rapamycin?”. I’m exaggerating about the 80% number a bit, but not by too much. I met up with a forum member who also attended and we sat down for lunch and it turned out 50% of the people at the table was taking rapamycin. Even a young girl who looked like a teenager, but who was actually a fairly newly minted PHD in Eric Verdin’s lab and who was probably late 20s said she and her boyfriend were both taking rapamycin too.
Lots of the researchers at the Buck are taking rapamycin. Any medical doctors there at the conference I spoke with were all taking rapamycin. I don’t have any way to gauge the actual percent, but I suspect it was likely around 30% of the group, and the only reason it might not be higher is because many of the people starting the longevity companies seem to be in their 30s, which is a little on the younger side to start rapamycin.
Other people were very enthusiastic about the latest SGLT2 inhibitor review article that is leading them towards wanting to take it for longevity.
I have no idea on the supplement side of things. My focus here was mostly on drugs and therapies at this conference.
7 Likes
Good question. Its mostly more just my impression and interpretation of what Marco Quarta was saying in his presentation about the new world of “Senolytics 2.0” and the implications of what he was saying. James Kirkland was not there, and nobody at the conference was discussing dasatinib and fisetin. But that is what seems to be the implication of all this new research being reported on. But - yes, don’t take my word as gospel. If I was planning to take dasatinib / fisetin, etc. I’d first talk to some of these researchers to see what the current thinking is around these interventions. It seems like the pendulum is swinging in a very different direction now.
3 Likes
I have been using it for the last 2 months in combination with Rapamycin cream and Tretinoin. Very hard to comment on the efficacy. The science base is interesting, but the aggressive marketing approach makes you wonder. It is obviously driven by commercial objectives.
2 Likes
Yes - its always hard to know where the science leaves off, and the marketing begins. Ultimately you have to make the call to continue buying or not based on your own results.
3 Likes
So what dosing of Rapamycin was trending? 6-9 mg weekly?
I didn’t get into dosing with enough people to get a read on that with any accuracy.
1 Like
Could organ-targeted senolytics then be chosen, based on which organs are aging the fastest ?
My apologies if I haven’t linked my post appropriately
2 Likes
Thank you Rap Admin. For the past few years, I keep approaching the starting line of Dasatinib and Fisetin but each time, I back off given I’m not convinced of the safety profile. I was approaching the starting line again and then read your post here. So backing off again. HA! Appreciate the reply.
1 Like
What is the safety profile issue with Fisetin?
1 Like
I’ve not heard anything regarding safety issues with Fiseten. I think the bigger issue would likely be the cancer drug dasatinib.
3 Likes
Hi RapAdmin,
Do you have a link to the “latest SGLT2 inhibitor review article”?
Thank you.
1 Like
1-s2.0-S0033062023001068-main.pdf (1.9 MB)
https://www.sciencedirect.com/science/article/pii/S0033062023001068?via%3Dihub
4 Likes
@DrG was nice enough to post it. But we also have links to all the latest good papers on canagliflozin and other SGLT2 inhibitors in this thread: Canagliflozin - Another Top Anti-aging Drug
I’ve thought about this a fair bit. I don’t think this will ever be financially viable or practical. Growing a body and keeping it in optimal health is a massive energy expenditure. You’d essentially need to double food production. Also our bodies are shaped by our environment, it may be possible to stimulate muscles and replicate exercise to keep the body in perfect health but it seems like an incredible amount of resources. Even if you were to say grow a body and do the transplant at the earliest possible window, which is probably around late adolescence. I think it’s more likely we’ll find a way to grow specific organs for transplant, but then even that probably requires an organ of a certain maturity for it to function well enough. It’s super interesting.
1 Like
Using what product? Please explain!
He’s talking about the OneSkin product. See the presentation above.